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Abstract
Helicobacter pylori (H. pylori) infection is highly prevalent in the human
population and may lead to severe gastrointestinal pathology including gastric
and duodenal ulcers, mucosa associated tissue lymphoma and gastric
adenocarcinoma. In recent years, an alarming increase in antimicrobial resistance
and subsequently failing empiric H. pylori eradication therapies have been noted
worldwide, also in many European countries. Therefore, rapid and accurate
determination of H. pylori’s antibiotic susceptibility prior to the administration of
eradication regimens becomes ever more important. Traditionally, detection of
H.pylori and its antimicrobial resistance is done by culture and phenotypic drug
susceptibility testing that are cumbersome with a long turn-around-time. Recent
advances in diagnostics provide new tools, like real-time polymerase chain
reaction (PCR) and line probe assays, to diagnose H. pylori infection and
antimicrobial resistance to certain antibiotics, directly from clinical specimens.
Moreover, high-throughput whole genome sequencing technologies allow the
rapid analysis of the pathogen’s genome, thereby allowing identification of
resistance mutations and associated antibiotic resistance. In the first part of this
review, we will give an overview on currently available diagnostic methods for
detection of H. pylori and its drug resistance and their implementation in H. pylori
management. The second part of the review focusses on the use of next
generation sequencing technology in H. pylori research. To this end, we
conducted a literature search for original research articles in English using the
terms “Helicobacter”, “transcriptomic”, “transcriptome”, “next generation
sequencing” and “whole genome sequencing”. This review is aimed to bridge the
gap between current diagnostic practice (histology, rapid urease test, H. pylori
culture, PCR and line probe assays) and new sequencing technologies and their
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potential implementation in diagnostic laboratory settings in order to
complement the currently recommended H. pylori management guidelines and
subsequently improve public health.
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Core tip: With worldwide increasing antibiotic resistance in Helicobacter pylori
(H.pylori), drug resistance phenotypes should be determined prior to the administration
of antibiotic eradication regimens. Our literature search yielded studies that focused on
the prediction of drug resistance phenotypes in H. pylori based on the presence of certain
point mutations in the bacterium’s genome using next generation sequencing (NGS)
technology. Thus, NGS technology may enable the implementation of rapid and accurate
genotypic drug susceptibility testing prior to the administration of antimicrobial therapy.
This may increase H. pylori eradication rates and ultimately improve patient
management.
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HELICOBACTER PYLORI PREVALENCE, EPIDEMIOLOGY
AND ANTIBIOTIC RESISTANCE
Current Helicobacter pylori prevalence and epidemiology
Initial acquisition of Helicobacter pylori (H. pylori) occurs primarily during childhood
and may persist throughout life[1]. Infection with H. pylori occurs worldwide, but there
are  substantial  geographic  differences  in  the  prevalence  of  infection  between
countries[2]. Multiple studies have demonstrated that socioeconomic status and ethnic
origin  of  the  population  are  strongly  associated  with  prevalence  of  H.  pylori
infection[3-5]. In Central and Northern Europe, H. pylori prevalence, excluding non-
European immigrants, was found to be around 24% to 32%[6-10]. Studies conducted in
Switzerland revealed a H. pylori  prevalence of 12%-20% in patients born in Swit-
zerland and a prevalence of 27% in immigrants[5,11].  H. pylori  can be divided into
relatively  distinct  populations  that  are  specific  for  large  geographical  areas:
HpEurope, hpSahul, hpEastAsia, hpAsia2, hpNEAfrica, hpAfrica1 and hpAfrica2[12-14].
The most prevalent H. pylori populations in Europe are hpEurope and hpNEAfrica[15].
Management of Helicobacter pylori infections
In most patients, H. pylori infection stays asymptomatic, but it can progress to various
gastrointestinal diseases including chronic active gastritis, peptic or duodenal ulcers,
gastric adenocarcinoma and mucosa associated tissue lymphoma[16]. Consequently, it
is a challenge for physicians to decide who should be tested for H. pylori infection and
who should be treated. In general, treatment is recommended in case of detection of
H. pylori infection, even in patients with asymptomatic H. pylori gastritis[17,18]. This
practice is supported by results from a systematic review of six randomized trials
evaluating  H.  pylori  eradication  therapy  to  prevent  gastric  cancer  in  healthy
asymptomatic individuals that found a significant reduction in the incidence of gastric
cancer[19]. However, this conclusion is mostly based on results of one interventional,
placebo-controlled trial that was conducted in China[20], a high incidence country for
gastric cancer. Therefore, further studies are needed in countries with low prevalence
of gastric cancer to evaluate the long-term cost-effectiveness of such interventions. In
the United Kingdom, two placebo-controlled trials conducted a H. pylori screening
and treatment program in the general population that reduced dyspepsia in patients,
who  receive  eradication  therapy[21,22].  Though,  they  concluded  that  targeted
eradication strategies in dyspeptic patients may be preferable. Therefore, the main
question in clinical practice remains: Who should be tested and consequently treated?
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Based on recent research, current guidelines (i.e., fifth Maastricht/Florence consensus
report[23]) recommend testing for H. pylori infection in situations described in Table 1.
Adult  patients  in  industrial  countries  that  have  been  successfully  treated  for
H.pylori  infection  rarely  show  reinfection  (reinfection  rate  of  2%)[24].  Therefore,
adequate  treatment  promises  high  eradication  efficacy  (see  next  chapter  for
antimicrobial therapy options) without recurrence of H. pylori infection. However,
there are major challenges in the treatment of H. pylori infection including increasing
resistance to antibiotics, which will be discussed in detail in the next section, and
compliance to therapy. A study performed in Switzerland showed that approximately
89% of the patients treated were considered as “good compliers”, meaning that they
consumed  more  than  85%  of  the  prescribed  doses[25].  In  this  study,  H.  pylori
eradication was inversely associated with poor compliance (P = 0.029) and the major
reason mentioned by the patients not complying with the treatment was side effects.
Antibiotic therapy indeed has non-negligible, short-term side effects such as diarrhea,
nausea, vomiting, bloating and/or abdominal pain. Moreover, it has been shown, and
also received media attention, that antibiotic treatment can alter the gut microbiota
richness  and  diversity[26,27],  possibly  deferring  health-conscious  patients  from
following through with antibiotic treatment.
Antibiotic resistance in Helicobacter pylori
The only currently available efficient treatment against H. pylori infection includes the
use of antibiotics. Main mechanisms of antibiotic resistance development in H. pylori
include mutations that impair the capability of antibiotics to bind the ribosomes and
interfere  with  protein  synthesis;  mutations  that  affect  DNA  replication  and
transcription;  mutations  that  modify  penicillin  binding  proteins,  involved  in
peptidoglycan biosynthesis[28]. As H. pylori easily develops drug resistance to single
antibiotics, combination therapy of several antibiotics is recommended. Combination
of antibiotics used in therapy should depend on local drug resistance rates estimated
in the respective country. Primary and acquired resistance to clarithromycin and
metronidazole has increased globally in the last years, diminishing the effectiveness of
conventional first-line treatment regimens and increasing treatment failures due to
drug-resistant H. pylori strains[29-33]. In particular, clarithromycin resistance increased
rapidly in several countries, to reach 30% in Japan and up to 50% in China[32]. Also in
Europe, an increasing trend of clarithromycin resistance in H. pylori can be observed
with an overall primary clarithromycin resistance rate of 17%[34]. However, prevalence
of clarithromycin resistance varies from 21% in Austria to 6% in Finland and the
Netherlands[10,35].  This  shows  that  clarithromycin  resistance  is  strongly  variable
between neighboring European countries emphasizing the need to examine drug
resistance separately in each geographic region to better guide empiric treatment
regimens. Metronidazole resistance, although not as important as clarithromycin
resistance,  also  significantly  reduces  treatment  efficiency  of  the  standard  triple
regimen[36].  Overall,  metronidazole resistance rates have been increasing in many
European countries[34,37-40], ranging from 14% to 33% in Europe[41-46]. The general trend
towards increasing resistance to first-line antibiotics in H. pylori has urged treating
physicians to prescribe alternative treatment regimens including tetracycline with a
PPI  and  a  bismuth  salt  or  the  use  of  levofloxacin  or  rifabutin-based  treatment
regimens[23,47,48]. However, these regimens require high patient compliance as antibiotic
therapy consist of many tablets that have to be taken daily for 10 to 14 d[49]. Incomplete
patient adherence to antibiotic therapy is directly associated with further resistance
development in H. pylori. Although levofloxacin resistance has not been studied as
extensively as clarithromycin and metronidazole resistance,  there is  also a trend
towards high primary and secondary levofloxacin resistance in H. pylori[35,38-40,50]. In
contrast, resistance to amoxicillin and tetracycline seems to be negligible in H. pylori (0
to 2%) in European countries[35,40,51-53]. Though tetracycline resistance does not seem
alarming yet in Western Europe, high resistance rates ranging from 5% to 19% were
found in Eastern European and Asian countries[54,55], emphasizing the need to prevent
further resistance spread in H. pylori.  Therefore,  similar as for first-line H. pylori
eradication regimens, administration of alternative antimicrobial therapy, especially
when levofloxacin based,  should be  guided by the  regional  and patient-specific
antimicrobial resistance patterns and knowledge about their local effectiveness.
CURRENT HELICOBACTER PYLORI DIAGNOSTICS
Several diagnostic methods are available for detecting H. pylori infections. They can be
broadly classified as invasive and non-invasive methods depending on the need to
retrieve  a  gastric  biopsy  from the  patient.  For  H.  pylori  detection,  endoscopy is
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Table 1  Who to test, summary of the recommendations from the fifth Maastricht/Florence consensus report[23]
Recommendations from the fifth Maastricht/Florence consensus report
Dyspepsia Subject to regional Helicobacter pylori prevalence, not applicable to patients
with alarm symptoms or older patients
Peptic ulcers Especially in aspirin and nonsteroidal anti-inflammatory drugs users with
history of peptic ulcer
Gastritis Especially in long-term proton-pump-inhibitor users
Gastric cancer In individuals at increased risk of gastric cancer
MALToma In individuals with localized early-stage MALToma
Iron deficiency anemia, idiopathic thrombocytopenic purpura, vitamin B12
deficiency
employed in combination with histology and/or culture from the gastric  biopsy
specimen. The major limitation of endoscopic examination is its relative invasiveness
and that  only  a  small  portion of  the  gastric  mucosa  can be  explored.  Therefore,
assessment of multiple gastric biopsy specimens is necessary to provide a global
picture of H. pylori  infection in the stomach[56,57].  When an endoscopy is indicated,
H.pylori can be detected by histology, rapid urease test (RUT), culture and polymerase
chain reaction (PCR)-based tests using gastric biopsy specimens[58,59]. The accuracy of
histology depends on a number of factors like the pathologist’s experience, density of
H. pylori colonization in the gastric mucosa, the quality and quantity of the clinical
specimen and subjective assessment of tissue changes.
The RUT is based on detecting urea produced by H. pylori, and results are obtained
within minutes to hours. The RUT is a cheap, rapid and generally highly specific
assay, but its sensitivity is affected if less than 104 bacterial cells are present in the
gastric biopsy, most probably leading to false-negative results. In some instances,
RUT specificity may be negatively affected by the presence of other urease producing
bacteria like Staphylococcus capitis urealiticum in the stomach that can lead to false-
positive test results[60]. Commercially available RUTs (e.g., HpFast, CLOTest, HpOne)
have reported specificities from 95% to 100%, but their sensitivity is moderate (85% to
95%)[17,61,62].
Successful isolation and cultivation of H. pylori from gastric biopsy specimens is a
challenging task that is affected by a number of factors like the quality of the clinical
specimen, occurrence of microbial commensal flora in clinical specimens, time interval
between sampling and culture and inappropriate transport conditions (temperature,
duration of air exposure, etc.). Furthermore, H. pylori culture requires highly trained
laboratory personnel and takes up to 7 d until samples can be reported as negative
and up to 2 wk until H. pylori has grown and an antibiogram can be provided to the
treating physician. H. pylori  culture from gastric biopsy specimens typically has a
sensitivity greater 90% and a specificity of 100%, when performed under optimal
conditions[63].  H. pylori  culture from clinical  specimens obtained by non-invasive
procedures, such as gastric juice, saliva and stool, is challenging and hampered by
low sensitivity[64-66], and therefore not recommended in routine diagnostics[67]. With the
global  emergence  of  antibiotic  resistant  H.  pylori  isolates  and  subsequently  in-
creasingly failing empiric first-line therapies, bacterial culture and phenotypic drug
susceptibility  testing  (DST)  remains  a  crucial  diagnostic  method  for  antibiotic
resistance surveillance and management of antibiotic treatment failures. However, it
is not recommended to do a full phenotypic DST before administration of first-line
treatment  as:  (1)  An  invasive  endoscopy  is  required  to  obtain  gastric  biopsy
specimens from the patient; (2) It is time consuming and costly; and (3) Less invasive,
molecular based methods are also able to detect clarithromycin resistance that is
momentarily the main cause of empiric treatment failure in European countries.
Due to these drawbacks,  numerous attempts have been made to develop non-
invasive diagnostic methods that avoid endoscopy. Classically, non-invasive tests for
H. pylori detection include stool antigen assays, serology and the frequently used urea
breath test (UBT)[68,69]. Antigen tests have been widely used for H. pylori detection in
clinical specimens like gastric juice, saliva, urine and stool[70-72].  However, antigen
detection methods, may suffer from poor specificity and sensitivity[70,71,73]. Different
stool antigen tests have been developed to detect H. pylori in stool specimens with a
sensitivity and specificity of 85% to 95%[17].  The UBT is the most frequently used
point-of-care test in the clinic with a sensitivity and specificity of 85% to 95%[17,74].
One limitation of the beforehand presented non-invasive diagnostic methods is that
they  can  solely  detect  H.  pylori  but  do  not  provide  information  on  the  drug
susceptibility of the bacterium. With increasing clarithromycin resistance rates in
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H.pylori,  rapid and accurate methods that can simultaneously detect H. pylori  and
assess its clarithromycin susceptibility offer high added value[10,44,75]. Clarithromycin
resistance in H. pylori  is  attributable,  in a majority of  cases,  to three single point
mutations  (A2146C,  A2146G  and  A2147G)  in  the  23S  rRNA  gene  that  can  be
accurately detected by PCR[76-79].  At the moment, there are a number of molecular
assays commercially available for H. pylori and clarithromycin resistance detection,
such as the H. pylori ClariRes (Ingenetix, Vienna, Austria), the Allplex H. pylori and
ClariR  (Seegene,  Korea),  the  Lightmix®H.  pylori  (TIBMolbiol,  Germany)  and the
H.pylori Taqman® real-time PCR assay (Meridian Bioscience, United States). These
assays mostly combine real-time PCR with melting curve analysis and are highly
specific and rapid (< 2 h) molecular methods that can be applied to gastric biopsy and
stool specimens[77,78]. Moreover, they can distinguish the three most common point
mutations (A2146G, A2147G and A2146C) in the 23S rRNA gene, which allows to
genotypically distinguish low- and high-level clarithromycin resistance[77]. However,
several studies found rather low sensitivity (ranging from 63% to 84%) of H. pylori
detection from stool specimens using the ClariRes assay when compared to stool
antigen test and H. pylori culture from gastric biopsy specimens[80-82]. Another study
validating the H. pylori Taqman® real-time PCR assay in stool specimens reported
higher  sensitivity  of  93.8%[79].  Therefore,  H. pylori  and clarithromycin resistance
detection directly from stool specimens may strongly depend on the DNA extraction
method  and  the  PCR  assay  used.  Consequently,  no  general  statement  on  the
diagnostic performance of PCR from stool can be made. One limitation of PCR assays
is, however, that they can just provide resistance information for clarithromycin. At
the moment, there is only one line probe assay (the Genotype HelicoDR assay; Hain
Life Sciences, Germany) commercially available that enables the detection of the most
common point mutations in the 23S rRNA (A2146G, A2147G and A2146C) and the
gyrA gene (N87K, D91G, D91N, D91Y) to determine clarithromycin and levofloxacin
susceptibility,  respectively.  The Genotype HelicoDR assay has  been reported to
accurately  detect  H.  pylori  and  clarithromycin  resistance  from  gastric  biopsy
specimens[83], but low concordance between H. pylori and clarithromycin resistance
detection from biopsy and stool specimens was found[84]. Moreover, the Genotype
HelicoDR assay has a long turn-around-time of 6 h compared to real-time PCR assays.
In  sum,  non-invasive  molecular  testing  from stool  would  have  the  following
advantages: (1) No invasive endoscopy is required; (2) Specimens can be stored longer
and do not require immediate processing; (3) Batching of specimens is possible; (4)
H.pylori detection and genotypic clarithromycin susceptibility screening can be done
within one working day (< 4 h); (5) Detection of hetero-resistance in specimens is
achievable when more than one H. pylori strain is present in a clinical specimen; (6)
Automated  DNA extraction  and real-time  PCR analysis  offers  a  high  degree  of
standardization and reproducibility. However, further studies are needed that assess
the  diagnostic  performance  of  optimized  DNA  extraction  procedures  and  non-
invasive stool PCRs (ideally targeting the 23S rRNA and gyrA gene) in comparison to
H. pylori culture based phenotypic DST from gastric biopsy specimens.
HELICOBACTER PYLORI TREATMENT AND PROPHYLAXIS
As H. pylori  antibiotic therapy is mostly based on clarithromycin, clarithromycin
resistance is the major determinant of antimicrobial treatment: In countries with low
clarithromycin resistance (i.e., < 15%), current first-line standard regimens for H. pylori
eradication  are  a  proton  pump  inhibitor  (PPI)-based  triple  therapy  (with
clarithromycin  in  combination with  metronidazole  or  amoxicillin)  or  a  bismuth
quadruple  therapy[23,85,86].  The  second  line  therapy  should  then  be  the  bismuth-
quadruple  (if  not  used  as  first-line  therapy)  or  a  triple  therapy  containing
fluoroquinolones. Choice of third-line therapy should be guided by phenotypic DST
or genotypic determination of drug resistance (associated costs for antibiotic therapy
are listed in Tables 2 and 3; approximate drug prices from Germany).
In  countries  with  high  clarithromycin  resistance  (i.e.,  >  15%),  metronidazole
resistance, although clinically less relevant, should be considered. If metronidazole
resistance is low, a triple therapy with PPI, amoxicillin and metronidazole can be
applied. If the dual resistance for clarithromycin and metronidazole is low, a bismuth
quadruple  or  a  concomitant  non-bismuth  quadruple  therapy  should  be  used.
However,  if  the dual resistance is  high,  bismuth containing quadruple therapies
should be used[23].
Vaccines against H. pylori have only recently been given serious consideration. In
animal models, initial vaccination tried oral immunization with H. pylori bacterial
lysate and cholera toxin as adjuvant[87]. Later on, intranasal and rectal delivery systems
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Table 2  Standard clarithromycin-based triple regimens using metronidazole or amoxicillin and associated costs
Drug Dose Costs (EUR) per dose Costs (EUR) for 7 d Costs (EUR) for 14 d
Standard triple regimen
(with metronidazole)
Clarithromycin 500 mg (twice daily) 1.1 15.4 30.8
Metronidazole 500 mg (three times
daily)
0.6 13.1 26.2
Pantoprazole (Proton-
pump inhibitor)
Standard dose (twice
daily)
0.1 1.6 3.2
In total 1.8 30.1 60.2
Standard triple regimen
(with amoxicillin)
Clarithromycin 500 mg (twice daily) 1.1 15.4 30.8
Amoxicillin 1 g (twice daily) 1.4 20.2 40.4
Pantoprazole (Proton-
pump inhibitor)
Standard dose (twice
daily)
0.1 1.6 3.2
In total 2.6 37.2 74.4
allowed  reducing  the  required  amount  of  purified  antigen  compared  to  oral
immunization.  Given  the  proposed  mechanism  of  action  involving  the  cellular
immune system[88], parenteral immunization with H. pylori antigens has been shown
to  result  in  a  significant  protection  from infection  in  mice  models[89].  However,
although clinical trials in human on immunization with H. pylori proteins have shown
adaptive immune mechanisms, they have since failed to consistently reduce bacterial
load[90]. More studies are needed in this area.
Due to increasing antibiotic resistances and side effects of antibiotics, alternative
therapies are of great interest. Probiotics have been shown to have positive effects on
eradication rates, prevention of adverse reactions and antibiotic-associated diarrhea
when combined to  eradication therapies.  A recent  systematic  review and meta-
analysis on probiotics as adjunct therapy found 19 randomized controlled trials, all
showing positive effects on at least one of the above-mentioned aspects[91]. However, it
appears that the number of meta-analysis on the topic exceeds the number of original
publications,  that,  even  in  randomized  controlled  fashion  show  large  detail
variance[92].  Interestingly,  a large and well  performed meta-analysis showed that
probiotic dose, duration, number of strains and duration of antibiotic treatment did
not affect the benefits conferred by probiotic adjunction[93],  reducing the scientific
plausibility  of  this  intervention  based  on  current  publications.  The  fifth
Maastricht/Florence consensus rapport acknowledges probiotics as beneficial in its
report, but evaluates the level of evidence as low to moderate with weak grade of
recommendation.  That  being  said,  probiotics  alone,  not  in  combination  with
antibiotics, have not been shown to efficiently eradicate H. pylori[94].  We as others
conclude  that  “more  data  are  definitely  needed  to  assess  the  direct  efficacy  of
probiotics against H. pylori”[23].
Licorice root is a botanical product frequently used in Chinese medicine. It has
detoxifying, antiulcer, anti-inflammatory, anti-viral and anticarcinogenic properties[95].
A randomized controlled trial on 120 H. pylori positive dyspeptic patients (with or
without peptic ulcer) assessed the effect of licorice in addition to clarithromycin-based
triple regimen. They showed that treatment response was 83.3% in the licorice-group
compared to 62.5% in the control group (P = 0.018). When distinguishing between
peptic  ulcer  disease  and  non-ulcer  dyspepsia,  significantly  better  response  to
treatment was only observed in patients with peptic ulcer (P = 0.034)[96].
Several other plant-based products are used for the treatment of gastrointestinal
disorders. Some of them have been mentioned as influencing H. pylori infections such
as  garlic,  cranberry  juice,  oregano  or  broccoli  sprouts  (non-exhaustive  list)[97].
However, few studies have identified the active ingredient or its mechanism of action
and dose/response or exposure level are not understood. Possible safety issues as
well  as  impact  of  resistance  on  efficacy  of  phyto-therapeutic  agents  has  to  be
addressed. Moreover, one review article mentioned the possibility of phage therapy
against H. pylori[98].
NEXT GENERATION SEQUENCING AND HELICOBACTER
PYLORI
In  order  to  get  an  overview  on  original  research  studies  that  focused  on  the
characterization  of  H.  pylori  by  next  generation  sequencing  (NGS)  a  PubMed
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Table 3  Alternative antibiotic Helicobacter pylori eradication therapy using quadruple or levofloxacin-based regimens and associated
costs
Regimen Drug Dose Costs(EUR) per dose Costs (EUR) for 7 d Costs (EUR) for 14 d
Bismuth quadruple
regimen
Tetracycline 500 mg (four times
daily)
0.6 12 16.8
Metronidazole 500 mg (three times
daily)
0.6 18.6 26.2
Pantoprazole (Proton-
pump inhibitor)
Standard dose (twice
daily)
0.1 2.2 3
Bismuth Subsalicylate Standard dose (three
times daily)
0.3 10 14
In total 1.6 42.8 60
Levofloxacin-based
regimen
Levofloxacin 500 mg (once daily) 2.7 27 38
Amoxicillin 1 g (twice daily) 1.4 28.8 40.4
Pantoprazole (Proton-
pump inhibitor)
Standard dose (twice
daily)
0.1 2.2 3.1
In total 4.2 58 81.5
Concomitant regimen Clarithromycin 500 mg (twice daily) 1.1 22 30.8
Amoxicillin 1 g (twice daily) 1.4 28.8 40.4
Metronidazole 500 mg (three times
daily)
0.6 2.2 3
Pantoprazole (Proton-
pump inhibitor)
Standard dose (twice
daily)
0.1 18.6 26.04
In total 3.2 72 100
MEDLINE  and  EMBASE  literature  search  was  conducted  without  any  time
constrains. Inclusion criteria: (1) Original research manuscripts; (2) Characterization of
clinical  human  H.  pylori  isolates;  (3)  Use  of  second  and/or  third  generation
sequencing technologies.  Exclusion criteria:  (1) Reviews, case reports,  comments,
letters; (2) Characterization of non-human H. pylori  isolates; (3) Original research
manuscripts that that did not use second or third generation sequencing technology.
First,  the terms “Helicobacter  pylori  AND transcriptome OR transcriptomic” were
searched and yielded 134 results, of which 12 were original research articles meeting
the inclusion criteria (Table 4). Second, a PubMed, MEDLINE and EMBASE search
using the terms “Helicobacter pylori AND next generation sequencing” was done that
yielded 102 results, of which 19 met the inclusion criteria (Table 5). And finally, a
PubMed, MEDLINE and EMBASE search with the terms “Helicobacter pylori  AND
whole genome sequencing” was done that yielded 89 results, of which 15 met the
inclusion criteria (Table 6).
The literature search mostly yielded basic research studies investigating a broad
spectrum of fundamental mechanism in H. pylori like the presence of genes associated
with bacterial  virulence[99-104]  and biofilm formation[105,106],  the characterization of
methylases[107], nudix hydrolases[108], restriction-modification (R-M) systems[109], exo-
and endo-ribonucleases[110]; and the transcriptional response of H. pylori to exposition
to different salt  concentrations[111],  different pH conditions[112],  heat  shock[113]  and
chemical agents like bismuth[114] and nickel[115]. Most of these studies initially depleted
ribosomal  RNA,  either  using  RiboZero  eukaryotic  rRNA  depletion  treatment
(Epicentre, Illumina)[112,113,116] or a rRNA modified capture hybridization approach[110],
and performed sequencing on an Illumina platform (Illumina, United States). More
applied studies focused on two main topics: The composition of the gut microbial
community in patients with H. pylori associated gastrointestinal pathology[117-123] or the
association between genotypic and phenotypic drug resistance in H. pylori[124-133].
The assessment of the human gut microbiome in health and disease is a hot topic in
medical sciences. Changes in the gut microbial composition after H. pylori infection
may induce pathogenesis  and various disorders.  However,  studies investigating
changes  in  the  microbial  community  composition  after  H.  pylori  infection  have
generated conflicting results. While some studies could not detect any significant
changes in the taxonomic composition of the gut microbiota[134-136], studies using NGS
technology have reported increased abundance of the families Xanthomonadaceae and
Enterobacteriaceae,  and  the  genera  Spirochaetae,  Streptococcus,  Lactobacillus,
Granulicatella,  Prevotella  and  Veillonella  in  response  to  H.  pylori  infection[137-139].
Moreover, some studies showed that antibiotic use to eradicate H. pylori affected the
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Table 4  A PubMed, MEDLINE and EMBASE search using the terms “Helicobacter pylori AND transcriptome OR transcriptomic” yielded
12 original research studies
Study Main finding Method Sequencing Ref.
1 Objective H. pylori 26695 culture grown
in liquid medium to log
phase
Depletion of ribosomal RNA
(RiboZero, Epicentre,
Illumina)
Estibariz et al[107]
Characterization of the
MTase JHP1050 in H. pylori
Main finding RNA-sequencing on an
Illumina HiSeq platform
(Illumina, United States; 1 ×
50 bp)
The MTase JHP1050, which
methylates GCGC sequences,
was found to be highly
conserved in all analyzed
H.pylori strains, with a
nucleotide sequence identity
> 87%. Absence of m5C
methylation had a significant
effect on H. pylori growth, led
to a significant reduction in
DNA uptake capacity, and
reduced the bacterial
protection against an excess
of copper
2 Objective H. pylori 26695 culture grown
in liquid medium to early log
phase
RNA-sequencing on a HTSeq
v0.6.1 platform[148]
Han et al[114]
Analyzing the impact of
bismuth on a diverse array of
intracellular pathways in
H.pylori
Main finding
Bismuth influences multiple
metabolic pathways and
suppresses energy
production in H. pylori
through disruption of the
central carbon metabolism of
the bacterium. Bismuth
initially perturbs the citric
acid cycle and then urease
activity, followed by the
induction of oxidative stress
and inhibition of energy
production, and in the
meantime, induces extensive
down-regulation in the
H.pylori metabolome
3 Objective H. pylori grown on non-
selective solid agar media
Depletion of ribosomal RNA
(RiboZero, Epicentre,
Illumina) RNA-sequencing
on an Illumina NextSeq
platform (Illumina)
Hathroubi et al[106]
Transcriptomic analysis to
assess the process of biofilm
formation in H. pylori
Main finding
H. pylori biofilm cells
displayed a distinct
transcriptomic profile. Lower
metabolism and stress
responses, likely associated
with the microenvironment
generated in the H. pylori
biofilm, could be
determinants of antimicrobial
tolerance and involved in the
persistence and survival of H.
pylori. However, there were
no specific genes up-or
downregulated that are
specific for biofilm formation,
suggesting that there is no
biofilm-specific set of genes
expressed. However, genes
encoding flagellar filaments
were upregulated in biofilm
cells and formed an integral
part of the biofilm matrix
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4 Objective H. pylori strain 7.13 was
grown in liquid medium to
mid exponential phase (OD
of 0.5)
Depletion of ribosomal RNA
(RiboZero, Epicentre,
Illumina)
Loh et al[111]
Transcriptional analysis of H.
pylori gene expression under
high salt conditions
Main finding
Differential expression of
multiple genes encoding
outer membrane proteins,
including adhesins (SabA,
HopA and HopQ) and
proteins involved in iron
acquisition (FecA2 and
FecA3) was observed.
Transcript levels of sabA,
hopA and hopQ were
increased, whereas transcript
levels of fecA2 and fecA3 were
decreased under high-salt
conditions. Functions
associated with the up- and
downregulated genes
included acetone metabolism,
acid survival, flagellar
synthesis and iron transport
RNA-sequencing on an
Illumina HiSeq 3000 platform
(Illumina; 2 × 75 bp)
5 Objective H. pylori strain G27 grown in
liquid medium, followed by
adaptation of the pH (3.0, 4.5,
6.0, 7.4, 8.0)
Depletion of ribosomal RNA
(RiboZero, Epicentre,
Illumina)
Marcus et al[112]
Transcriptional analysis of H.
pylori gene expression under
different pH conditions
Main finding RNA-sequencing on an
Illumina HiSeq 2500 platform
(Illumina; 1 × 50 bp)
About 250 genes were
induced, and an equal
number of genes were
repressed at acidic pH. Genes
encoding for antioxidant
proteins, flagellar structural
proteins, type-IV secretion
system (T4SS)/Cag-
pathogenicity island, FoF1-
ATPase, and proteins
involved in acid acclimation
were highly expressed at
acidic pH
6 Objective Different H. pylori strains
grown in liquid medium to
mid exponential phase (OD =
0.7) with/without heat shock
treatment
Depletion of ribosomal RNA
(RiboZero, Epicentre,
Illumina)
Pepe et al[113]
Characterization of the heat
shock protein repressor
(HspR) binding sites in
H.pylori
Main finding RNA-sequencing on an
Illumina GAIIX platform
(Illumina; 1 × 85 bp)
HspR is involved in the
regulation of different crucial
cellular functions through a
limited number of genomic
binding sites. There is high
sequence conservation in the
HAIR motif (an HspR-
associated inverted repeat of
Streptomyces spp.) among
H.pylori strains. Site-directed
mutagenesis demonstrated
that the HAIR motif is
fundamental for HspR
binding and that additional
nucleotide determinants
flanking the HAIR motif are
required for complete
binding of HspR to its
operator sequence spanning
over 70 bp of DNA
7 Objective Gastric biopsy specimens
from patients with H. pylori
infection and premalignant
tissue changes
Depletion of ribosomal RNA
(RiboZero, Epicentre,
Illumina)
Thorelll et al[116]
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Analysis of the composition
of the transcriptionally active
microbial community and
H.pylori gene expression in
gastric biopsy specimens
from patients with H. pylori
infection and premalignant
tissue changes
RNA-Sequencing on an
Illumina HiScanSQ platform
(Illumina; 2 × 100 bp)
Main finding
Although H. pylori infection
did not change the bacterial
diversity, H. pylori abundance
was positively correlated
with the presence of
Campylobacter, Deinococcus
and Sulfurospirillum.
Quantification of H. pylori
gene expression found high
expression of genes involved
in pH regulation and nickel
transport
8 Objective H. pylori strains grown in
liquid medium and treated
with high nickel (500 μM
Ni2+) concentrations
Depletion of ribosomal RNA
(RiboZero, Epicentre,
Illumina)
Vannini et al[115]
Characterization of the Nickel
dependent transcriptional
regulator (NikR) in H. pylori
Main finding RNA-sequencing on an
Illumina MiSeq platform
(Illumina; 1 × 76 bp)
NikR not only regulates
metal-ion transporters but
also virulence factors, non-
coding RNAs, as well as
toxin-antitoxin systems in
response to nickel stimulation
9 Objective H. pylori strains grown to mid
exponential growth phase
(OD = 0.7)
RNA-sequencing on an
Illumina HiSeq 2000 platform
(Illumina; 1 × 97 bp)
Bischler et al[108]
Characterization of Nudix
hydrolases in H. pylori
Main finding
H. pylori encodes two
proteins resembling Nudix
enzymes. One of them,
HpRppH, is an RNA pyro-
phosphohydrolase that
triggers RNA degradation in
H. pylori, whereas the other,
HP0507, lacks such activity.
Transcriptional analysis
revealed at least 63 potential
HpRppH targets in H. pylori
10 Objective H. pylori strains grown in
liquid medium to mid
exponential phase (OD of 0.5)
Depletion of ribosomal RNA
by a rRNA modified capture
hybridization approach from
MICROBExpress kit
(Ambion, Invitrogen, Life
Technologies)
Redko et al[110]
Characterization of the exo-
and endoribonuclease RNase
J in H. pylori and its putative
targets
Main finding
Strong depletion of RNase J
led to a massive increase in
the steady-state levels of non-
rRNAs. mRNAs and RNAs
antisense to open reading
frames. In contrast, non-
coding RNAs expressed in
the intergenic regions were
much less affected by RNase J
depletion. This suggests that
RNase J is a major RNase
involved in degradation of
most cellular RNAs in
H.pylori
RNA-sequencing on an
Illumina HiSeq 2000 platform
(Illumina; 1 × 50 bp)
11 Objective Analysis of
methylated DNA sites
throughout the H. pylori
genome for several closely
related H. pylori strains
H. pylori strains (HPYF1 and
HPYF2) grown to mid
exponential phase (OD of 0.4)
RNA-sequencing on an
Illumina HiSeq 2000 platform
(Illumina)
Futura et al[149]
Main finding
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Overall, the methylome was
highly variable among closely
related H. pylori strains. DNA
sequence motifs for
methylation could be
assigned to a specific
homology group of the target
recognition domains in the
specificity-determining genes
for Type I and other
restriction-modification
systems. Knocking out one of
the Type I specificity genes
led to transcriptome changes
12 Objective H. pylori grown on non-
selective solid agar media
Total RNA was digested with
DNase I
Sharma et al[150]
Characterization of the
transcriptome of H. pylori,
and construction of a
genome-wide map of H.pylori
transcriptional start sites and
operons
RNA-sequencing was
performed on a Roche 454
FLX platform (Roche, Basel,
Switzerland) and on a
Genome Analyzer II platform
(Illumina; 1 × 76 bp)Main finding
Discovery of hundreds of
transcriptional start sites
within operons, and opposite
to annotated genes,
indicating that complexity of
gene expression from the
small H. pylori genome is
increased by uncoupling of
polycistrons and by genome-
wide antisense transcription.
An unexpected number of
approximately 60 small
RNAs including the epsilon-
subdivision counterpart of
the regulatory 6S RNA and
associated RNA products,
and potential regulators of
cis- and trans-encoded target
messenger RNAs were
discovered
Their objective, employed sequencing method and main finding is briefly described in the table. H. pylori: Helicobacter pylori.
proliferation of the gut microbial community and altered microbial diversity[140-142],
though; species diversity recovered to pre-treatment levels upon long-term follow-
up[141,142]. This encourages the calculation of a microbial dysbiosis index based on the
abundances  of  certain  gut  microbial  taxa  in  H.  pylori  infected  patients[143].  The
dysbiosis index enables to distinguish patients with different H. pylori  associated
gastrointestinal  pathologies[138],  and  may  potentially  help  to  guide  patient  ma-
nagement.
One limitation of using DNA based techniques for the determination of bacterial
abundances and the calculation of a dysbiosis index is that all microorganisms, which
are  present  in  the  human  gut,  are  detected,  including  dead  bacteria  and  DNA
contaminations (e.g., from incautious sampling, unsterile laboratory procedures or
from extraction and sequencing chemicals). In contrast, using meta-transcriptomics
allows to investigate only the viable and transcriptionally active proportion of the
human gut microbial community.  A recently conducted study by Thorell  et  al[116]
nicely demonstrated that meta-transcriptomics is a very sensitive method that can be
applied directly on gastric biopsy specimens. They found that gastric biopsies from
patients initially classified as H. pylori uninfected by conventional methods, contained
actively replicating H. pylori, though in lower numbers than biopsy specimens initially
scored  as  H.  pylori  positive.  This  suggests  that  H.  pylori  may  be  present  in  low
abundance  in  individuals,  in  whom conventional  methods have failed to  detect
H.pylori.  It  would be interesting to investigate if  these patients develop H. pylori
infection at a later stage and which circumstances may trigger or reinforce infection.
Moreover, it would be interesting to investigate if probiotic treatment in these patients
would reduce the transcriptionally active H. pylori population to undetectable levels,
potentially preventing disease development.
The other research studies identified in our literature review focused on using NGS
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Table 5  A PubMed, MEDLINE and EMBASE search using the terms “Helicobacter pylori AND next generation sequencing” yielded 19
original research studies
Study Main finding Method Sequencing Ref.
1 Objective DNA extraction from gastric
biopsy specimens
Targeted 16S rRNA
sequencing on an Ion
S5XLplatform (Thermo Fisher
Scientific, United States)
Han et al[117]
Assessment of the correlation
between the microbial gut
community composition and
the degree of inflammatory
cell infiltration, endoscopic
findings and the
gastrointestinal disorders
symptom severity index
(PAGI-SYM)
Main finding
Histological and endoscopic
gastritis was associated with
the abundance of H. pylori
and that of commensal
bacteria in the stomach. The
abundances of Variovorax
paradoxus and Porphyromonas
gingivalis were correlated
with histological gastritis, but
not with endoscopic or
symptomatic gastritis. The
total PAGI-SYM score
showed a stronger correlation
with the duodenal microbiota
(Prevotella nanceiensis and
Alloprevotella rava) than with
the gastric microbiota
(H.pylori, Neisseria elongate,
and Corynebacterium
segmentosum)
2 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
MiSeq platform (Illumina,
United States)
Miftahussurur et al[128]
Resistance to metronidazole
rifaximin, rifabutin,
furazolidone, garenoxacin
and sitafloxacin was
investigated in Indonesian
H.pylori strains
Main finding
Furazolidone-, rifabutin-, and
sitafloxacin-based therapies
might be considered as
alternative regimens to
eradicate metronidazole and
clarithromycin resistant
H.pylori in Indonesian
patients. Moreover,
sitafloxacin but not
garenoxacin should be
considered for eradication of
levofloxacin-resistant H.pylori
strains
3 Objective DNA extraction from gastric
FFPE tissue blocks
16S rRNA targeted
sequencing on an Ion Torrent
(Thermo Fischer) platform
Nezami et al[132]
Detection of H. pylori
mutations that are known to
confer resistance to
clarithromycin, levofloxacin,
and tetracycline directly from
formalin-fixed paraffin-
embedded (FFPE) gastric
biopsy specimens using next
generation sequencing
Main finding
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Therapy failure correlated
with the number of mutated
genes: no failure in cases with
no mutations (0/15), 19%
(5/27) failure in cases with
one gene mutation, and 69%
(11/16) failure in cases with
more than one mutated gene.
Common 23S rRNA
mutations (A2146G or
A241G) were present in 88%
(14/16) of failed cases as
opposed to only 10% (4/42)
of eradicated cases (P <
0.001). NGS can be used on
clinical specimens collected
during standard of care
testing to detect mutations
that correlate with increased
risk of treatment failure
4 Objective DNA extraction from gastric
biopsy specimens
16S rRNA targeted
sequencing on an Illumina
HiSeq 2500 platform
(Illumina; 2 × 250 bp)
Yu et al[118]
Assessment of the changes in
the microbial esophagal
community composition in
Chinese patients with reflux
esophagitis and healthy
volunteers using
metagenomic high-
throughput DNA sequencing
Main finding
Moderate changes in the
microbial community
composition were found in
patients with reflux
esophagitis and compared
with the healthy volunteers.
At the phylum level, only
Bacteroidetes differed between
the groups, being less
abundant in the reflux
esophagitis group. The
overall number and diversity
of species tended to be lower
in reflux esophagitis patients,
but there were no significant
differences between the
groups. Three genera,
Prevotella, Helicobacter and
Moraxella, were obviously
depleted in reflux esophagitis
patients
5 Objective DNA extraction from gastric
biopsy specimens
16S rRNA targeted
sequencing on an Illumina
MiSeq platform (Illumina)
Zhao et al[119]
Characterization of H. pylori-
induced alterations in the
gastric and tongue coating
microbiota and evaluation of
potential impacts on human
health in patients with
chronic gastritis
Main finding
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Significant alterations of the
gastric microbiota were
found in H. pylori-positive
(cagA-positive) samples
represented by a decrease in
bacterial diversity, a reduced
abundance of Roseburia and
increased abundances of
Helicobacter and Haemophilus.
At the community level,
functions involved in biofilm
formation, mobile element
content, and facultative
anaerobiosis were
significantly decreased in the
microbial community in
H.pylori-positive subjects.
Presence of CagA was linked
to an increased proportion of
Gram-negative bacteria in the
stomach, thereby
contributing to an up
regulation of
lipopolysaccharide
biosynthesis
6 Objective DNA extraction from gastric
biopsy specimens or surgical
specimens of non-neoplastic
gastric mucosa adjacent to the
tumor
16S rRNA targeted
sequencing on an Ion PGM
Torrent platform (Thermo
Fischer Scientific)
Ferreira et al[138]
Characterization of the
microbial community in
patients suffering from
gastritis and gastric cancer
Main finding
The gastric carcinoma
microbiota was characterized
by reduced microbial
diversity, decreased
abundance of H. pylori and
the enrichment of other
bacterial genera, mostly
represented by intestinal
commensals. The
combination of these taxa
into a microbial dysbiosis
index revealed that dysbiosis
can be used to discriminate
between gastritis and gastric
carcinoma. Analysis of the
functional features of the
microbiota was compatible
with the presence of a
nitrosating microbial
community in carcinoma
7 Objective DNA extraction from stool
specimens
16S rRNA targeted
sequencing on an Illumina
MiSeq platform (Illumina)
Gotoda et al[142]
Assessment of the changes in
the gut microbiome after
H.pylori eradication therapy
in teenagers
Main finding
Alpha diversity revealed that
both species richness and
evenness were recovered to
pre-treatment levels at 2 mo
after H. pylori eradication
therapy. Although H. pylori
eradication therapy caused
short-term dysbiosis,
microbial diversity was
restored in healthy teenagers
8 Objective DNA extraction from stool
specimens
16S rRNA targeted
sequencing on an Illumina
MiSeq platform (Illumina; 2 ×
300bp)
Iino et al[120]
Assessment of the association
between H. pylori infection
and the abundance of
Lactobacillus species in the gut
microbial community in
Japanese patients
Main finding
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The relative abundance of
Lactobacillus in H. pylori-
infected subjects with severe
atrophic gastritis was higher
compared with patients with
mild atrophic gastritis and
without atrophic gastritis (P <
0.001) and non-infected
subjects (P < 0.001). The
proportion of Lactobacillus
salivarius was high in
H.pylori-infected subjects
while that of Lactobacillus
acidophilus was high in non-
infected subjects
9 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
MiSeq platform (Illumina)
Aftab et al[103]
Determination of the
sequences of virulence genes
(cagA and vacA) and seven
housekeeping genes by next
generation sequencing
Main finding
All H. pylori strains were
considered Western-type, and
73.2% of them carried cagA.
Patients infected with cagA-
positive strains had more
severe histological scores
than patients infected with
cagA-negative strains. Thus,
the low incidence of gastric
cancer in Bangladesh might
be attributable to the high
proportion of less-virulent
H.pylori genotypes
10 Objective DNA extraction from gastric
biopsy specimens
16S rRNA targeted
sequencing on an Illumina
MiSeq platform (Illumina; 1 ×
500 bp)
Klymiuk et al[139]
Assessment of the bacterial
microbiome in a total of 30
homogenized and frozen
gastric biopsy samples from
eight geographic locations.
Main finding
H. pylori infection of the
gastric habitat dominates the
gastric microbiota in most
patients and is associated
with a significant decrease of
the microbial alpha diversity.
Moreover, some bacterial
genera like Actinomyces,
Granulicatella, Veillonella,
Fusobacterium, Neisseria,
Helicobacter, Streptococcus, and
Prevotella were associated
with the presence of H. pylori
11 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
MiSeq platform (Illumina)
Miftahussurur et al[124]
Characterization of
levofloxacin, metronidazole,
clarithromycin, amoxicillin
and tetracycline resistance in
H. pylori isolated from 158
dyspeptic patients in Santo
Domingo
Main finding
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Clarithromycin and
amoxicillin resistance were
low (3.1% and 1.6%), and no
resistance to tetracycline was
found. In contrast,
metronidazole and
levofloxacin resistance were
high (82.8% and 35.9%). Most
levofloxacin-resistant H.pylori
strains had an amino acid
substitution at codon 87 or 91
in the gyrA gene. Many
different rdxA and frxA
mutations in metronidazole-
resistant H. pylori strains were
found without synergistic
effects. Novel mutations in
dppA, dppB, fdxA and fdxB,
irrespective of rdxA and frxA
mutations were associated
with different levels of
metronidazole resistance in
H. pylori
12 Objective DNA extraction from stool
specimens
16S rRNA targeted
sequencing on an Illumina
MiSeq platform (Illumina; 2 ×
300 bp)
Yanagi et al[121]
Assessment of the influence
of antimicrobials on both, the
gut microbiota community
composition and the plasma
ghrelin level in H. pylori-
infected patients, who
underwent eradication
therapy (amoxicillin,
clarithromycin and proton-
pump inhibitors)
Main finding
The Bacteroidetes:Firmicutes
(B:F) ratio was significantly
increased 3 months after than
before antibiotic treatment (P
< 0.01). A significant decrease
in the concentration of active
ghrelin (P < 0.01) in the
plasma was observed before
and 3 mo after antibiotic
therapy
13 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
HiSeq 2000 and MiSeq
platform (Illumina; 2 × 150 bp
and 2 × 300 bp)
Hashinaga et al[100]
Comparison of cagA and vacA
sequences of H. pylori strains
isolated from patients with
gastric cancer and MALT
lymphoma in Japan
Main finding
Conventional genotyping of
cagA and vacA showed no
significant difference between
patients with gastric cancer
and MALT lymphoma. When
comparing full protein
sequences of CagA and VacA,
four novel loci were found on
CagA, and three loci were
detected on VacA. Significant
differences were observed at
one CagA locus between
gastritis and MALT
lymphoma H. pylori strains,
and at one VacA locus
between gastritis and gastric
cancer H. pylori strains
14 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
MiSeq platform (Illumina)
Miftahussurur et al[126]
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Characterization of
levofloxacin, metronidazole,
clarithromycin, amoxicillin
and tetracycline resistance in
H. pylori isolates from
Indonesia
Main finding
Clarithromycin, amoxicillin
and tetracycline resistance
were low (9.1%, 5.2% and
2.6%). In contrast, high
resistance rates to
metronidazole (46.7%) and
levofloxacin (31.2%) were
found. Metronidazole
resistant H. pylori strains
showed different rdxA amino
acid substitutions, and the
23S rRNA A2147G mutation
occurred in clarithromycin
resistant H. pylori. However,
one clarithromycin resistant
H. pylori strain had a novel
mutation in rpl22 without an
A2147G mutation. Amino
acid exchanges at N87
and/or D91 of gyrA were
associated with levofloxacin-
resistance
15 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
MiSeq platform (Illumina)
Miftahussurur et al[127]
Characterization of H. pylori
strains isolated from 146
patients in Kathmandu,
Nepal
Main finding
H. pylori was not resistant to
amoxicillin and tetracycline.
In contrast, metronidazole
resistance was extremely high
(88.1%), while clarithromycin
resistance was modestly high
(21.4%). Most of
metronidazole resistant
H.pylori strains had diverse
rdxA and frxA mutations.
Novel mutations in dppA
(A212, Q382 and I485) and
dapF (L145, T168, E117, V121,
R221) aside from missense
mutations in rdxA were
found in metronidazole
resistant H. pylori strains.
Amino acid exchanges at N87
and/or D91 in gyrA were
predominantly found in
levofloxacin-resistant H.pylori
strains
16 Objective A metronidazole-resistant
strain was cultured from the
metronidazole-susceptible
H.pylori reference strain 26695
by exposure to low
concentrations of
metronidazole
Sequencing on an Illumina
HiSeq 2000 platform
(Illumina; 2 × 90 bp)
Binh et al[129]
Characterization of wildtype
and metronidazole resistant
H. pylori reference strain
26695 in order to elucidate
the molecular basis of
metronidazole resistance and
the involved genes in H.pylori
Main finding
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Mutated sequences in rdxA
were successfully
transformed into the H. pylori
reference strain 26695, and
the transformants showed
resistance to metronidazole.
Transformed H. pylori isolates
containing a single mutation
in rdxA showed a low MIC
(16 mg/L), while those
containing mutations in both
rdxA and frxA showed a
higher MIC (48 mg/L).
Moreover, mutations in rpsU
may play a role in
metronidazole resistance
17 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
platform (Illumina)
Furuta et al[104]
H. pylori strains were isolated
from the members of five
families to investigate the
microevolution and
adaptation of the H. pylori
genome using next
generation sequencing and
multi-locus sequence typing
Main finding
Detection of nucleotide
substitutions revealed likely
transmission pathways
involving children.
Nonsynonymous mutations
were found in virulence-
related genes (cag, vacA,
hcpDX, tnfα, ggt, htrA and the
collagenase gene), outer
membrane protein (OMP)
genes and other cell surface-
related protein genes, signal
transduction genes and
restriction-modification genes
18 Objective H. pylori strain UM032 was
grown on non-selective agar
medium
Sequencing on a RS
instrument (Pacific
Biosciences, United States;
yielding > 300 × average
genome coverage) and on an
Illumina MiSeq platform
(Illumina; 2 × 300 bp)
Lee et al[109]
Elucidating the biological
significance of the restriction-
modification (R-M) system in
the physiology and
pathogenesis of H. pylori
Main finding
Strain UM032 contains a
relatively large number of R-
M systems, including some
MTase activities with novel
specificities. Specifically, 17
methylated sequence motifs
corresponding to 1 Type I
and 16 Type II R-M systems
were found
19 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
HiSeq 2000 platform
(Illumina; 2 × 90bp)
Miftahussurur et al[122]
Assessment of the prevalence
of H. pylori infection and
evaluation of human
migration patterns in the
remote areas of North
Sulawesi using next-
generation sequencing and
multi-locus sequence typing
Main finding
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H. pylori prevalence was low
(14.3% in adults and 3.8% in
children). One H. pylori strain
carried East Asian type cagA
(ABD type), vacA s1c-m1b,
iceA1, jhp0562-positive/β-
(1,3), oipA “status-on”.
Phylogenetic analyses
showed that the strain
belonged to hspMaori type, a
major type observed in native
Taiwanese and Maori tribes
Their objective, employed sequencing method and main finding is briefly described in the table. H. pylori: Helicobacter pylori.
technology for  the  detection  of  drug resistance  mutations  in  H.  pylori  and their
corrleation with phenotypic drug resistance[124-133]. Collectively, these studies show that
clarithromycin resistance is based on point mutations at nucleotide positions A2146
and A2147 in the 23S rRNA gene[125-127,133]. Additional mutations in rpl22 and infB were
reported  in  clarithromycin-resistant  H.  pylori  strains  without  23S  rRNA  mu-
tations[126,127]. However, some methodological concerns should be considered. First,
multiple gastric biopsy specimens should be used for H. pylori  culture in order to
enhance sensitivity and detect H. pylori sub-populations. Second, multiple colonies
should be picked from agar plates for DNA extraction and library preparation to not
miss drug resistant sub-populations. Third, H. pylori strains should be sequenced with
sufficient  coverage  to  detect  hetero-resistance.  Fourth,  multiple  susceptible  and
resistant H. pylori  strains should be sequenced to distinguish naturally occurring
polymorphisms from mutations potentially conferring drug resistance.
Levofloxacin resistance in H. pylori  has been found associated with amino acid
exchanges at codon 87 and/or 91 in the gyrA  gene[124-127].  No synergistic effect on
levofloxacin resistance has been found in H. pylori  strains that carried additional
mutations in gyrB.  Rifampicin resistance has been reported to be associated with
amino acid exchanges in the rifampicin resistance determining region of the rpoB
gene[125]. In contrast, the prediction of metronidazole resistance based on genotypic
information remains challenging for H. pylori. Most metronidazole resistant H. pylori
strains have been reported to carry multiple rdxA and frxA mutations[124,125,127]; though,
also metronidazole resistant strains without mutations in rdxA and/or frxA were
reported[125]. Moreover, frameshift and resistance mutations in rdxA and frxA have also
been reported in metronidazole susceptible H. pylori  strains[125].  Collectively,  this
suggests  that  more  studies  are  needed  investigating  the  association  between
polymorphisms detected in rdxA, frxA, mdaB, omp11 and rpsU and other genes and
phenotypic  metronidazole  resistance.  NGS  may  also  be  used  to  detect  novel
mutations associated with metronidazole resistance in genes such as dapF, dppA, dppB,
fdxA, and fdxB[124,127].
Another area of applicationf of NGS technology is the investigation of mutations
associated with resistance against new antibiotic agents like the rifamycins rifabutin
and  rifaximin,  the  quinolones  garenoxacin  and  sitafloxacin  and  the  nitrofuran
antimicrobial agent furazolidone[128]. Analysis of rpoB sequences of rifaximin resistant
H. pylori strains showed amino acid exchanges at I837, A2414, K2068, Q2079 in rpoB,
while  amino acid exchanges  at  N87 and D91 in  gyrA  were  associated with  high
levofloxacin resistance in H. pylori. No H. pylori strain was phenotypically resistant to
garenoxacin  or  sitafloxacin,  suggesting  a  higher  genetic  barrier  to  resistance
development, and that multiple mutations or synergistic effects may be required to
infer  resistance  against  these  antibiotics.  NGS  can  further  be  employed  for  the
identification of putative candidate mutations in phenotypically resistant H. pylori
strains without known resistance mutations[129,130]; and to identify efflux pump genes
that may be involved in the development of drug resistance in H. pylori[131].
CONCLUSION AND POTENTIAL FUTURE DIRECTIONS
During the last years, antibiotic resistance in H. pylori has continuously increased, also
in Western and Central Europe, where antibiotic resistance has been traditionally
considered low. This alarming trend leads to question the usefulness of the currently
employed  “test-and-treat”  strategy  and  to  considered  determining  H.  pylori’s
antibiotic resistance prior to eradication therapy in order to achieve better treatment
efficiency.  When considering the current costs for H. pylori  eradication regimens
(Table 2 and Table 3; approximate drug prices from Germany), depending on local
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Table 6  A PubMed, MEDLINE and EMBASE search using the terms “Helicobacter pylori AND whole genome sequencing” yielded 15
original research studies
Study Main finding Method Sequencing Ref.
1 Objective DNA extraction from biopsy
specimens
Sequencing on an Illumina
HiSeq 2500 platform
(Illumina, United States; 2 ×
50 bp)
Ailloud et al[123]
Investigation of H. pylori
evolution during infection
and population dynamics
inside the gastric
environment
Main finding
Phylogenetic analyses
suggested location-specific
evolution and bacterial
migration between gastric
regions. Migration was
significantly more frequent
between the corpus and the
fundus than with the antrum,
suggesting that physiological
differences between antral
and oxyntic mucosa
contribute to spatial
partitioning of H. pylori
populations. Associations
between H. pylori gene
polymorphisms and stomach
niches suggested that
chemotaxis, regulatory
functions and outer
membrane proteins
contribute to the specific
adaptation to the antral and
oxyntic mucosa
2 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
MiSeq platform (Illumina; 2 ×
150 bp)
Lauener et al[125]
Single nucleotide
polymorphisms (SNPs) were
detected in H. pylori isolates
by whole genome sequencing
and their correlation with
phenotypic resistance to
clarithromycin,
metronidazole, tetracycline,
levofloxacin and rifampicin
was assessed
Main finding
Overall, there was high
congruence of > 99% between
phenotypic drug
susceptibility testing results
for clarithromycin,
levofloxacin, and rifampicin
and SNPs identified in the
23S rRNA, gyrA and rpoB
genes. However, it was not
possible to infer a resistance
phenotype for metronidazole
based on the occurrence of
distinct SNPs in rdxA and/or
frxA
3 Objective H. pylori strains grown on
solid non-selective agar
media
Sequencing on an Illumina
HiSeq platform (Illumina; 2 ×
150 bp)
Chen et al[133]
Characterization of
polymorphisms in
Clarithromycin resistant and
susceptible H. pylori strains
using whole genome
sequencing
Main finding
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No mutations known to be
associated with
clarithromycin resistance,
except for the controversial
T2182C mutation, were
detected. Single nucleotide
variants (SNVs) in multidrug
efflux transporter genes and
HP0605 were significantly
different between
clarithromycin resistant and
susceptible H. pylori strains.
No significant difference in
SNVs of membrane proteins
of the RND family or MFS
(HP1181) family were found
4 Objective H. pylori strains isolated from
patients with abdominal
pain, gastritis, gastric or
duodenal ulcers
Sequencing on an Illumina
MiSeq platform (Illumina)
Quintana-Hayashi et al[151]
Characterization of the
binding ability, adhesion
modes, and growth of H.
pylori strains isolated from
pediatric patients with
abdominal pain, gastritis,
gastric or duodenal ulcers
Main finding
Increased adhesion capacity
of pediatric peptic ulcer
disease (PUD) H. pylori
strains to human gastric
mucins compared to the non-
ulcer dyspepsia (NUD)
strains both at neutral and
acidic pH, regardless if the
mucins were positive for
Lewis b (Leb), Sialyl-Lewis ×
(SLex) or LacdiNAc. In
addition to babA positive
strains being more common
among PUD associated
strains, H. pylori babA positive
strains bound more avidly to
gastric mucins than NUD
babA positive strains at acidic
pH. Binding to Leb was
higher among babA positive
PUD H. pylori strains
compared to NUD strains at
neutral, but not acidic, pH.
PUD derived babA-knockout
mutants had attenuated
binding to mucins and Leb at
acidic and neutral pH, and to
SLex and DNA at acidic pH
5 Objective H. pylori strain B128 isolated
from a gastric biopsy of a
patient with gastric ulceration
was challenged with
low/high salt concentrations
Sequencing on an Illumina
MiSeq platform (Illumina)
Noto et al[99]
H. pylori was continuously
cultured in vitro under low
iron or high salt conditions to
characterize fur genetic
variation. Moreover, fur
sequence variation was
assessed in 339 clinical H.
pylori strains
Main finding
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Exposure to low iron or high
salt selected for a specific
single nucleotide
polymorphism in the fur gene
(FurR88H) in H. pylori.
Among the isolates
examined, 17% of H. pylori
strains isolated from patients
with premalignant lesions
harbored the FurR88H
variant, compared to only 6%
of H. pylori strains from
patients with non-atrophic
gastritis. These results
indicate that specific genetic
variation arises within H.
pylori strains during in vivo
adaptation to conditions
conducive for gastric
carcinogenesis
6 Objective H. pylori strains were
cultured on solid non-
selective agar media
Sequencing on an Illumina
MiSeq platform (Illumina; 2 ×
300 bp)
Zhang et al[152]
Comparison of
homogenization vs enzymatic
digestion protocols for DNA
extraction from gastric,
esophageal and colorectal
biopsies and survey of the
microbial content and
composition using whole
genome sequencing
Main finding
Neither method
demonstrated preferential
extraction of any particular
clade of bacteria, nor
significantly altered the
detection of Gram-positive or
Gram-negative organisms.
However, although the
overall microbial community
composition remained very
similar and the most
prevalent bacteria could be
detected effectively using
either method, the precise
community structure and
microbial abundances
between the two methods
were different. The
homogenization extraction
method provided higher
microbial DNA content and
higher read counts from
human tissue biopsy samples
of the gastrointestinal tract
7 Objective H. pylori strains isolated from
gastric biopsies of patients
suffering from dyspepsia
Sequencing on an Illumina
MiSeq platform (Illumina; 2 ×
300 bp)
Kumar et al[153]
Whole genome sequencing
and comparative analysis of
three H. pylori strains isolated
from three Arab patients
Main finding
The three genomes clustered
along with HpEurope strains
in the phylogenetic tree
comprising various H. pylori
lineages. The three genomes
possessed a complete cag-
pathogenicity island with an
AB-C type EPIYA motif
8 Objective H. pylori strains were isolated
from gastric biopsy
specimens of patients with
chronic gastritis, gastric ulcer,
duodenal ulcer and gastric
cancer
Sequencing on an Illumina
MiSeq platform (Illumina; 2 ×
300 bp)
Ogawa et al[101]
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Characterization of cagL and
cagI in H. pylori isolated from
patients in Southeast Asia
with chronic gastritis, gastric
ulcer, duodenal ulcer and
gastric cancer
Main finding
CagL motifs were highly
conserved among the H.pylori
isolates. CagL E59 and I234 in
the C-terminal motif were
more common in H.pylori
isolates from gastric cancer
patients. The CagI C-terminal
motif was completely
conserved across all H. pylori
isolates
9 Objective H. pylori strains were isolated
from gastric biopsy
specimens of patients with
non-ulcer dyspepsia, gastric
ulcer and duodenal ulcer
Sequencing on an Illumina
MiSeq platform (Illumina; 2 ×
150 bp)
Silva et al[102]
Characterization of the
expression of virB genes,
encoding parts of the type-IV
secretion system (T4SS)/Cag-
pathogenicity island, in
H.pylori strains isolated from
Western patients with
different gastrointestinal
malignancies
Main finding
The region spanning from
virB2 to virB10 constitutes an
operon, whose expression is
increased in the adherent
fraction of bacteria during
infection, as well as in both
adherent and nonadherent
fractions at acidic conditions.
10 Objective H. pylori culture from gastric
biopsy specimens
Sequencing on an Illumina
HiScanSQ platform (Illumina;
2 × 100 bp)
Thorell et al[154]
Characterization of H. pylori
strains isolated in Nicaragua
Main finding
The Nicaraguan isolates
showed a phylogenetic
relationship with West
African H. pylori isolates in
whole genome sequence
comparison and with
Western and urban South-
and Central-American
isolates using multi-locus
sequence analysis. A majority
(77%) of the isolates carried
the cancer-associated
virulence gene cagA and also
the s1/i1/m1 allele of the
vacuolating cytotoxin gene
that is linked to increased
severity of disease. Moreover,
it was found that Nicaraguan
isolates have a blood group-
binding adhesin (babA)
variant highly similar to
previously reported babA
sequences from Latin
America H. pylori isolates
11 Objective H. pylori reference strain
26695, cagA and Cag-
pathogenicity island deletion
mutants were cultured
Sequencing on an Illumina
MiSeq platform (Illumina)
Wong et al[105]
Characterization of genes
associated with biofilm
formation in H. pylori
Main finding
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Genes identified to be
associated with biofilm
formation in H. pylori
included alpha (1,3)-
fucosyltransferase, flagellar
protein, 3 hypothetical
proteins, outer membrane
proteins and a Cag-
pathogenicity island protein
(CagPAI). These genes play a
role in bacterial motility,
lipopolysaccharide synthesis,
Lewis antigen synthesis,
adhesion and/or the type-IV
secretion system (T4SS).
Deletion of cagA and CagPAI
confirmed that CagA and
T4SS were involved in
H.pylori biofilm formation
12 Objective H. pylori was isolated from a
gastroscopic antral biopsy
specimen of a patient with
chronic gastritis
Sequencing on an Illumina
MiSeq platform (Illumina; 2 ×
150 bp)
Cao et al[155]
H. pylori was isolated from a
gastroscopic antral biopsy
specimen of a 53-year-old
male patient with chronic
gastritis. Whole genome
sequencing was applied to
these isolates, and
bioinformatic tools were used
to investigate the within host
evolution of H. pylori isolates
Main finding
The H. pylori genomes fall
into two clades, reflecting
colonization of the stomach
by two distinct strains. The
lineages have accumulated
diversity during an estimated
2.8 and 4.2 yr of evolution.
Around 150 clear
recombination events
between the two clades were
found. Imputed ancestral
sequences also showed
evidence of recombination
between the two strains prior
to their diversification, and it
was estimated that they have
both been infecting the same
host for at least 12 yr
13 Objective Nineteen H. pylori clinical
isolates were isolated from
gastric epithelium biopsy
specimens
Sequencing on an Illumina
MiSeq platform (Illumina; 2 ×
300 bp)
Iwamoto et al[131]
Whole genome sequencing of
12 clarithromycin resistant
and 7 susceptible H. pylori
strains was done to identify
novel genetic factors that
reduce susceptibility to
clarithromycin
Main finding
In clarithromycin resistant
H.pylori strains specific point
mutations in the 23S rRNA
gene were found. In addition,
genetic variants of four gene
clusters (hp0605-hp0607,
hp0971-hp0969, hp1327-
hp1329, and hp1489-hp1487)
of efflux pumps homologues,
which have been previously
implicated in multi-drug
resistance, were found
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14 Objective H. pylori reference strain
26695 was used as
amoxicillin-sensitive
reference strain and as
parental strain to create in
vitro resistant H. pylori
isolates
Sequencing on an Illumina
Genome Analyzer (Illumina)
Qureshi et al[130]
Investigation of the
occurrence of genetic
mutations that contribute to
amoxicillin resistance in
H.pylori when exposed to
increasing concentrations of
amoxicillin in vitro
Main finding
Using a whole genome
sequencing approach,
mutations in a number of
genes were identified,
notably pbp1, pbp2, hefC, hopC
and hofH. Mutations in pbp1,
hefC, hopC, hofH, and possibly
pbp2, contributed to H. pylori
high-level amoxicillin
resistance
15 Objective H. pylori reference strain
26695 and H. pylori strain J99
were grown on solid non-
selective agar media
Sequencing on a PGM (Ion
Torrent, Thermo Fischer
Scientific, United States) and
an Illumina MiSeq platform
(Illumina)
Perkins et al[156]
Next generation sequencing
of the H. pylori reference
strains J99 and 26695 and
bioinformatic analysis of the
sequencing data using
publicly available algorithms.
The accuracy of the coding
sequence assemblies was
compared to the originally
published sequences
Main finding
With the Ion Torrent PGM, an
inherently high-error rate in
the raw sequencing data was
found. With the Illumina
MiSeq, significantly more
non-covered nucleotides
were found when using
Illumina Nextera XT
compared to the Illumina
Nextera library preparation
method. The most accurate
de novo assemblies were
found when using the
Nextera technology.
However, extracting an
accurate multi-locus sequence
type was inconsistent
compared to the Ion Torrent
PGM. The Cag-pathogenicity
island failed to assemble onto
a single contig in all
technologies but was more
accurate using the Nextera
technology. The Illumina
MiSeq Nextera method was
found as the most accurate
method for whole genome
sequencing of H. pylori and
de novo assembly of its
genome
Their objective, employed sequencing method and main finding is briefly described in the table. H. pylori: Helicobacter pylori.
resistance rates, initial molecular determination of H. pylori drug susceptibility may be
cost efficient, especially, when considering that costs for PCR assays (< 20 EUR) and
WGS  (<  100  EUR)  have  consistently  decreased  over  the  last  years.  In  contrast,
endoscopy (100-250 EUR) and H. pylori culture-based phenotypic DST (80-100 EUR)
remains costly.
However,  in  order  to  determine  drug  resistance  phenotypes  prior  to  the  ad-
ministration of antibiotics, resistance information must be more rapidly available,
ideally  with  non-invasive  methods  that  do  not  require  endoscopy.  Diagnostic
methods, like line probe assays or culture based phenotypic DST, that provide drug
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resistance information have long turn-around-times and require a gastric biopsy that
can just be obtained by invasive endoscopy. In contrast, currently available, non-
invasive diagnostic methods can only detect resistance mutations in the 23S rRNA
gene of H. pylori (e.g., PCR from stool). This may be insufficient in areas with high
metronidazole resistance or if levofloxacin- or rifampicin-based regimens have to be
administered to patients. Our literature search yielded studies that focused on the
prediction of  drug resistance phenotypes based on the presence of  certain point
mutations in the H. pylori genome. However, all of these studies used culture H. pylori
isolates or DNA extraction from gastric biopsy specimens. In an effort to decrease
turn-around-times and apply diagnostic workflows that do not require endoscopy,
future studies should aim at detecting H. pylori and associated resistance mutations
directly from clinical specimens (gastric biopsies or stool) using meta-genomic and/or
meta-transcriptomic sequencing.  Our literature search yielded primary research
articles  that  have  successfully  applied  WGS directly  on  gastric  biopsies  for  the
detection of H. pylori[116,132,144,145]. One major limitation for the cost-effectiveness and
feasibility of clinical meta-genomic and meta-transcriptomic sequencing has always
been  the  rather  big  amounts  of  RNA  or  DNA  required  for  subsequent  library
preparation and high human DNA background requiring deep sequencing. There has
been a  tremendous development  in  this  area,  and in-house developed[146,147]  and
commercial  protocols  [e.g.,  RiboZero  (Illumina),  RiboGold  (Illumina),  MIC-
ROBExpress (Ambion, Invitrogen)] are becoming available for the depletion of human
DNA  or  the  enrichment  of  bacterial  DNA  prior  to  performing  WGS,  thereby
increasing the efficiency and cost-effectiveness  of  NGS due to  less  human DNA
background in clinical specimens.
In conclusion, NGS technology has opened up new avenues for the characterization
of  complex  microbial  communities,  including  those  associated  with  H.  pylori
associated gastrointestinal disease. Particularly exciting is the promise of culture-
independent approaches to H. pylori detection and assessment of antibiotic resistance.
In  the  diagnostic  laboratory,  NGS may enable  the  implementation of  rapid  and
accurate  genotypic  DST prior  to  the  administration of  antimicrobial  therapy for
H.pylori eradication.
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